← Back to Search

Basic Needs Navigation for Type 2 Diabetes

Phase 2
Waitlist Available
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-75 years old
Diagnosed with type 2 diabetes
Must not have
Have cognitive or hearing impairments that significantly impede participation in telephone-based survey and intervention protocols
Individuals not living independently (e.g., nursing homes, rehab or correctional facilities)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if having someone to help with basic needs like food and housing can improve diabetes management in low-income adults. The study focuses on adults with type 2 diabetes who struggle with basic needs. By addressing these needs, the trial aims to see if participants can better manage their diabetes and improve their health.

Who is the study for?
This trial is for adults aged 18-75 with type 2 diabetes and Medicaid, who have at least one unmet basic need like food or housing. They must have had a HbA1c test recently and not be in case management, pregnant, living in care facilities, or have significant cognitive or hearing impairments.
What is being tested?
The study compares a 'basic needs navigation' intervention to usual care among those with type 2 diabetes on Medicaid. It aims to see if helping with needs like food and housing can improve blood sugar control (HbA1c levels) and overall health outcomes.
What are the potential side effects?
Since the intervention involves social support rather than medication, typical drug side effects are not expected. However, participants may experience changes in stress levels or emotional well-being due to the nature of receiving additional support.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.
Select...
I have been diagnosed with type 2 diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have significant hearing or cognitive issues affecting phone communication.
Select...
I do not live independently due to being in a nursing home, rehab, or correctional facility.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
HbA1c
Secondary study objectives
Health-related Quality of Life

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Basic needs navigationExperimental Treatment1 Intervention
Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan (usual care) as well as a navigator for 6 months to address any unmet basic needs, provide instrumental and emotional social support, and improve self-management capabilities.
Group II: Usual careActive Control1 Intervention
Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan including access to a physician network, case management resources, and other educational and health-focused resources and activities.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Type 2 Diabetes include lifestyle modifications, metformin, and insulin therapy. Lifestyle modifications, such as diet and exercise, improve insulin sensitivity and promote weight loss, thereby reducing blood glucose levels. Metformin decreases hepatic glucose production and increases insulin sensitivity. Insulin therapy directly lowers blood glucose levels by facilitating cellular glucose uptake. These treatments are essential for Type 2 Diabetes patients as they address both physiological and behavioral aspects of the disease, leading to better glycemic control and overall health outcomes.
Systematic Review and Meta-Analysis of Good Self-Care Practice among People Living with Type 2 Diabetes Mellitus in Ethiopia: A National Call to Bolster Lifestyle Changes.Defining Usual Care in Clinical Trials.Effectiveness of lay-led, group-based self-management interventions to improve glycated hemoglobin (HbA1c), self-efficacy, and emergency visit rates among adults with type 2 diabetes: A systematic review and meta-analysis.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,991 Previous Clinical Trials
2,295,411 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,446 Previous Clinical Trials
4,331,359 Total Patients Enrolled
Louisiana Healthcare ConnectionsUNKNOWN
1 Previous Clinical Trials
1,460 Total Patients Enrolled

Media Library

Basic needs navigation Clinical Trial Eligibility Overview. Trial Name: NCT03940209 — Phase 2
Type 2 Diabetes Research Study Groups: Usual care, Basic needs navigation
Type 2 Diabetes Clinical Trial 2023: Basic needs navigation Highlights & Side Effects. Trial Name: NCT03940209 — Phase 2
Basic needs navigation 2023 Treatment Timeline for Medical Study. Trial Name: NCT03940209 — Phase 2
~79 spots leftby Nov 2025